...
首页> 外文期刊>Prescrire international >Too many patients exposed to metopimazine in France
【24h】

Too many patients exposed to metopimazine in France

机译:太多的患者在法国接触到甲莫昔嗪

获取原文
获取原文并翻译 | 示例
           

摘要

Data from France's national health insurance system show that the number of patients exposed to domperidone fell from about 4.8 million to 2 million per year between 2012 and 2016, while the number of patients exposed to metopimazine increased from about 3 million to over 4 million. Domperidone, metopimazine and metoclopramide are neuroleptics used as antiemetics (1).The serious cardiac disorders these drugs can provoke have attracted increasing attention since the 2000s and mean that their harm-benefit balance in transient nausea and vomiting is unfavourable (see pp. 128) (2). Approximately 4.8 million adults were exposed to domperidone in France in 2012, about 3 million of whom were not receiving cancer treatment (1,3).These figures came from an analysis we conducted of data from the "General Sample of Health Insurance Beneficiaries" ("Echantilllon generaliste de beneficiaires"), a representative sample consisting of 1 in 97 of the population covered by France's national health insurance system (a) (1). Has exposure to domperidone decreased in France since 2012? And how many patients have been exposed to metopimazine and metoclopramide? This article presents the main findings of our analysis of EGB data on exposure to these neuroleptics (3).
机译:来自法国国家健康保险制度的数据表明,2012年和2016年暴露于DoMperidone的患者的数量从约480万到200万,而暴露于甲模甲胺的患者数量从约300万到超过400万。 DOMPERIDONE,二甲嘧啶和甲基氯普胺是用作止吐剂(1)的神经胶质蛋白。严重的心脏病这些药物可以引发,自2000年代以来,这些药物可能引起了越来越长的关注,并且意味着它们在短暂的恶心和呕吐方面的危害性效益平衡是不利的(见第128页) (2)。 2012年法国大约480万人接触到DOMPERIDONE,其中约300万未接受癌症治疗(1,3)。这些数字来自我们从“健康保险受益者一般样本”( “Echantilllon Generaliste de Benfficiaires”),该代表样品由法国国家健康保险制度(a)(1)覆盖的97人组成。自2012年以来,在法国下降了Domperidone吗?还有多少患者暴露于甲昔嗪和甲基氯普胺?本文介绍了我们对暴露于这些神经抑制药(3)的EGB数据分析的主要结果。

著录项

  • 来源
    《Prescrire international》 |2018年第193期|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号